Pharma and healthcare sector mutual funds have been the standout performers, delivering a positive return of around 1.34% in the last month due to favorable Q3 earnings outlook, government PLI incentives, and domestic demand growth. Experts advise diversified equity investments to mitigate concentration risks.
